Evidence map›Paper›PMID 25706885›Full record

Trial reportBone marrow transplantation2015

Subsequent malignant neoplasms in pediatric cancer patients treated with and without hematopoietic SCT.

J D Pole, D Darmawikarta, A Gassas, M Ali, M Egler, M L Greenberg, J Doyle, P C Nathan, T Schechter

Abstract readClinical TrialComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Subsequent primary neoplasm risk among survivors of cancer in adolescence and young adulthood: a population-based study from Alberta, Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Observational
  11. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

J D Pole1] Research Unit, Pediatric Oncology Group of Ontario, Toronto, ON, Canada [2] Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
D DarmawikartaResearch Unit, Pediatric Oncology Group of Ontario, Toronto, ON, Canada.
A GassasThe Hospital for Sick Children, Department of Pediatrics, Division of Hematology/Oncology, University of Toronto, Toronto, ON, Canada.
M AliThe Hospital for Sick Children, Department of Pediatrics, Division of Hematology/Oncology, University of Toronto, Toronto, ON, Canada.
M EglerThe Hospital for Sick Children, Department of Pediatrics, Division of Hematology/Oncology, University of Toronto, Toronto, ON, Canada.
M L Greenberg1] Research Unit, Pediatric Oncology Group of Ontario, Toronto, ON, Canada [2] The Hospital for Sick Children, Department of Pediatrics, Division of Hematology/Oncology, University of Toronto, Toronto, ON, Canada [3] Department of Surgery, University of Toronto, Toronto, ON, Canada.
J DoyleDepartment of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada.
P C NathanThe Hospital for Sick Children, Department of Pediatrics, Division of Hematology/Oncology, University of Toronto, Toronto, ON, Canada.
T SchechterThe Hospital for Sick Children, Department of Pediatrics, Division of Hematology/Oncology, University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric cancer patients are at increased risk of subsequent malignant neoplasms (SMNs). However, little is known about the contribution of hematopoietic SCT (HSCT) to the development of SMNs. The objective of this study was to compare the incidence of SMNs in a population cohort of childhood cancer survivors treated with and without HSCT. A cohort of 7986 children (age 0-14 years) diagnosed with cancer in the province of Ontario, Canada between 1985 and 2009 was identified in POGONIS (Pediatric Oncology Group of Ontario Networked Information System), a population-based active cancer registry, and linked to a clinical HSCT database. Among this cohort, 796 patients had an HSCT as part of their primary treatment. Of the 375 allogeneic HSCT patients, 14 (3.7%) developed a SMN at a median follow-up of 12.3 years (range: 2.0-22.9 years). Of the 421 autologous HSCT patients, 8 (1.9%) developed a SMN at a median of 4.5 years (range: 1.3-14.3 years). Of the 7190 patients who did not receive an HSCT, 160 (2.2%) developed a SMN at a median follow-up of 6.8 years (range: 0.0-24.9 years). The 15-year cumulative incidence of SMN was 3.1% among the allogeneic HSCT group, 2.5% among the autologous group and 2.3% in the non-HSCT group. The cumulative incidence curves for the allogeneic HSCT and non-transplant groups only diverged after ~15 years from primary diagnosis. Our findings further corroborate the observation that children who undergo allogeneic HSCT are at a significantly increased risk of developing SMN compared with pediatric cancer survivors treated without HSCT.

Indexed as

Databases, FactualHematopoietic Stem Cell TransplantationRegistriesAdolescentAdultAllograftsAutograftsChildChild, PreschoolFemaleFollow-Up StudiesHumansIncidenceInfantMaleNeoplasms, Second Primary

Identifiers

PMID25706885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.